Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658626 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06658626 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 8 participants.
The verdict
NCT06658626, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what happens to enlicitide chloride labeled with \[¹⁴C\] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.
Interventions
- DRUG [¹⁴C]Enlicitide chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2023-08-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06658626
The ClinicalTrials.gov registry entry for NCT06658626 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]Enlicitide chloride is the first listed.
NCT06658626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06658626 about?
NCT06658626 is a clinical study titled "A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)". The purpose of this study is to learn what happens to enlicitide chloride labeled with \[¹⁴C\] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.
What is the current status of trial NCT06658626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-03-10. Estimated completion is 2023-08-02.
What interventions are being tested in trial NCT06658626?
The interventions under investigation include: [¹⁴C]Enlicitide chloride (DRUG).
Who is sponsoring clinical trial NCT06658626?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.